Uncategorized

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.

InnoCare Pharma, a leading biopharmaceutical company, announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma.

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to March 2023.

When a person notifies their employer that they have a disability, the company must make a good-faith effort to adjust to enable the employee to continue in their job. 

As companies prioritize in-person work, many have begun to do more to incentivize a reluctant workforce to come into the office.

Sobre la evolución de la actitud y el pensamiento científicos de la población

An administrative stay of a Texas district court ruling will remain in place through Friday, pushing out a Supreme Court decision in the closely watched case over the drug mifepristone.

Carrying out the restructuring will result in a charge of about $7 million to $9 million in the first half of 2023, the company reported.

A study abstract inadvertently posted online showed J&J and Legend’s therapy, Carvykti, reduced the risk of disease progression or death by more than 70% over standard drugs.